NDAORALTABLET, EXTENDED RELEASE
Approved
May 2016
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
JENTADUETO XR (linagliptin and metformin hydrochloride) by Boehringer Ingelheim is dipeptidyl peptidase 4 inhibitors [moa]. Approved for dipeptidyl peptidase 4 inhibitor [epc]. First approved in 2016.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JENTADUETO XR is a fixed-dose combination of linagliptin (a DPP-4 inhibitor) and metformin hydrochloride (an extended-release formulation) approved in 2016 for type 2 diabetes management. It works by inhibiting dipeptidyl peptidase-4, which increases incretin levels and enhances glucose-dependent insulin secretion, while metformin reduces hepatic glucose production. The combination provides dual mechanism glycemic control in a single extended-release tablet.
$30MPart D
Peak11.1 years to LOEProduct is in peak lifecycle phase with stable Medicare utilization; commercial teams are focused on market maintenance rather than growth expansion.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
JENTADUETO XR careers are concentrated in market maintenance and commercial execution roles, with limited research or clinical development opportunity. Teams are focused on defending market share against newer mechanisms and optimizing formulary placement in a declining DPP-4 class.
Brand ManagerMedical Science Liaison
Worked on JENTADUETO XR at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.